302 patents
Utility
Chemical Compounds
11 Jan 24
JEFFREY WALLACE JOHANNES, SUDHIR MAHADEO HANDE, AVIPSA GHOSH, XIAOLAN ZHENG, MARTIN PACKER, SEBASTIEN LOUIS DEGORCE
Filed: 14 Sep 23
Utility
Substituted indazoles as IRAK4 inhibitors
9 Jan 24
Ina Terstiege, Stefan Schiesser, Yafeng Xue, Hui-Fang Chang, Anna Ingrid Kristina Berggren
Filed: 1 Dec 21
Utility
Automated Assessment of Wound Tissue
4 Jan 24
A method of assessing a wound in a subject is provided.
Yinhai WANG, Adrian Mark FREEMAN
Filed: 11 Nov 21
Utility
N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
2 Jan 24
Jonas Brånalt, Maria Johansson, Anneli Nordqvist, Marianne Swanson
Filed: 12 Jun 23
Utility
N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES
21 Dec 23
Jonas BRÅNALT, Maria JOHANSSON, Anneli NORDQVIST, Gavin O'MAHONY, Marianne SWANSON
Filed: 20 Jun 23
Utility
Adjuvant Durvalumab in Combination with Chemotherapy for Treatment of Cancer
21 Dec 23
The disclosure generally relates to methods for treating cancer in a patient using durvalumab in combination with chemotherapy based on the patient's minimal residual status.
Phillip DENNIS, Lynne POOLE, Rena MAY
Filed: 11 Oct 21
Utility
PCSK9 Inhibitors and Methods of Use Thereof
21 Dec 23
The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.
Michael H. Serrano-Wu, Brian K. Hubbard, Virendar Kaushik, Doug Daniels
Filed: 25 Jan 23
Utility
Automated detection of safety signals for pharmacovigilance
19 Dec 23
An embodiment may involve obtaining a set of pre-defined features and a new document; extracting a subset of the pre-defined features from within new document; applying a natural language model to the new document, wherein the natural language model was pre-trained using scientific or medical literature and fine-tuned using a corpus of documents; applying a feature-based model to the subset of the pre-defined features extracted from the new document, wherein the feature-based model was trained with the pre-defined features and the respective labels of the documents; and applying an aggregation model to the classifications of the new document produced by the natural language model and the feature-based model, wherein the aggregation model was trained with prior classifications produced by the natural language model and the feature-based model so that the aggregation model produces a further classification of the new document representing its relevance to pharmacovigilance.
Alexandre Kiazand, Robert Hernandez, Antoni Wisniewski, Douglas Domalik, Tony Gill
Filed: 22 Jul 21
Utility
Method of treating fatty liver disease
12 Dec 23
The present disclosure provides methods of treating or preventing fatty liver disease and/or lowering cholesterol and LDL cholesterol levels in a subject.
Daniel Linden, Richard Lee, Stefano Romeo, Huynh-Hoa Bui
Filed: 21 Sep 21
Utility
Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
28 Nov 23
Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed.
Anna Maria Langkilde
Filed: 18 Jul 19
Utility
Combination Therapy for Treating Cancer
23 Nov 23
The present disclosure relates, in general, to therapeutic combinations, and to corresponding methods of treatment, pharmaceutical compositions, and kits.
ELISABETTA LEO
Filed: 7 Oct 21
Utility
Amido Heteroaromatic Compounds
23 Nov 23
Daniel Tor PETTERSEN, Stéphanie Marcelle GUERET, Nidhal SELMI, Erik Lars MALMERBERG, Tord Bertil INGHARDT, Jan Åke LINDBERG, Jens Peter BRANDT, Jon Paul JANET, Björn Erik Anton HOLM
Filed: 18 May 23
Utility
Compounds and Their Use In Treating Cancer
23 Nov 23
Iacovos Neal Michaelides, Ulf Börjesson, Thomas George Christopher Hayhow, Jason Grant Kettle, Gavin William Collie, Robert Ian Storer, Christoph Grebner, Matthew William Dampier Perry, Sharanjeet Kaur Bagal, Charlene Fallan
Filed: 29 Sep 21
Utility
Combination
23 Nov 23
The present invention features methods of treating cancer with an immunomodulatory agent, such as an anti-PD-L1 antibody or an antigen-binding fragment thereof, and an antisense compound targeted to STAT3 in a subject in need thereof.
Richard WOESSNER, Patricia Elizabeth MCCOON, Paul Dermot LYNE
Filed: 13 Oct 22
Utility
Biomarkers for Predicting Overall Survival In Recorrent/metastatic Head and Neck Squamous Cell Carcinoma
23 Nov 23
The present disclosure generally relates to methods for treating head and neck squamous cell carcinoma patients based on use of blood-based tumor mutation burden, PD-L1 expression, expression levels of immunomodulators, pro-angiogenesis markers and pro-inflammatory markers and/or identification of mutations in circulating tumor DNA.
Weimin LI, Jiabu YE, Han SI, Nassim MORSLI, Qu ZHANG, Sophie WILDSMITH
Filed: 12 May 21
Utility
Arginase Inhibitors and Methods of Use Thereof
16 Nov 23
Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON, Jianyan WANG, Steve COOK, Dedong WU
Filed: 10 Jul 23
Utility
Combination of Zibotentan and Dapagliflozin for the Treatment of Endothelin Related Diseases
16 Nov 23
The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
Peter GREASLEY, Christine AHLSTRÖM, Stanko SKRTIC, Robert MENZIES, Anne-Kristina MERCIER, Mikael SUNNÅKER
Filed: 23 Jun 23
Utility
ANTI-IFNAR1 Dosing Regime for Subcutaneous Injection
16 Nov 23
The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease.
Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Sr., Joachim ALMQUIST, Thomas ROUSE
Filed: 21 Apr 23
Utility
Pharmaceutical composition
14 Nov 23
The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
Filed: 6 May 21
Utility
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
14 Nov 23
Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jacqueline Anne Macritchie, Nicholas John Palmer
Filed: 10 Sep 22